Phase 4 Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Crohn's disease according to recognised European guidelines (ECCO guidelines)
- People who are 18 years of age or older at the time of signing consent to participate
- People who have no medical reasons that would prevent them from taking the study medication, guselkumab
- People whose Crohn's disease is currently active, shown by reported symptoms such as abdominal pain or frequent bowel movements, and a stool test result showing inflammation above a certain level (faecal calprotectin above 250 ug/g)
- People who have had active disease confirmed within the past 2 months through a camera examination of the bowel, an MRI scan, or an intestinal ultrasound
- People who are not currently taking part in any other interventional research study
- People who have either never received an advanced Crohn's disease therapy before, or who have previously received one or more advanced therapies, provided this aligns with the approved use of guselkumab for Crohn's disease
- Women who could potentially become pregnant must have a negative blood pregnancy test at the first study visit
Who may not be able to join:
- People who are under a legal protection order or guardianship arrangement
- People who have previously been treated with a medication that targets a substance called IL-23
- People who are currently using another advanced therapy at the same time as guselkumab
- People who have a stoma (an opening on the abdomen used to redirect the bowel)
- People who are currently pregnant or breastfeeding
- People whose Crohn's disease mainly affects the area around the back passage (perianal disease)
- People who have a currently active and significant infection, or who have HIV, Hepatitis B, Hepatitis C, or active tuberculosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mathurin Fumery, Investigator, Hospital of Amiens, France
Phone: 0033 6 85 29 97 64
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
- Steroid free clinical remission (SFCR) associated with fecal calprotectin < 250 ug/g at Week 48; - Steroid free clinical remission (SFCR) associated with fecal calprotectin < 250 ug/g at Week 48
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.